Novo Nordisk shares tumble as weight-loss drug trial data disappoints Financial TimesNovo Nordisk Falls Most on Record After New Weight Drug Disappoints BloombergOzempic maker’s shares plunge after failed weight-loss trial The TelegraphNovo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it CNNNovo Nordisk shares plunge after CagriSema obesity drug trial disappoints ReutersNovo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial Yahoo FinanceNovo Nordisk’s new weight-loss drug works better, but not as well as expected MarketWatchNovo Crashes 20% After New Obesity Drug Misses Forecasts. Lilly, Viking, Amgen Jump. Investor’s Business DailyNovo’s next-gen obesity drug misses expectations in closely watched trial BioPharma Dive
https://news.google.com/rss/articles/CBMicEFVX3lxTFAxNTdDR2s0RG9RUUxQeHVkdlp4YVRnNTVnRHZnQ0FEWURHbjdZeWxaaDdfenQ1eGNMaWYyU1hOWDRGVjVqR3ZuZ25wbnJpMGtlcXZmYXd3Skh6OFdsSjd4YnRzaG5ROU9WRlRCdENMOXM?oc=5
Novo Nordisk shares tumble as weight-loss drug trial data disappoints – Financial Times
